Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1210/endocr/bqaa127 http://scihub22266oqcxt.onion/10.1210/endocr/bqaa127 32730568!7438701!32730568     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Endocrinology 2020 ; 161 (9): ä Nephropedia Template TP {{tp|p=32730568|t=2020. Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes |pdf=|usr=}}{{32730568}} gab.com Text Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes JO: Endocrinology http://www.kidney.de/pget.php?&tw=1&pmid=32730568 #FOAvip Severe outcomes and death from the novel coronavirus disease 2019 (COVID-19) appear to be characterized by an exaggerated immune response with hypercytokinemia leading to inflammatory infiltration of the lungs and acute respiratory distress syndrome. Risk of severe COVID-19 outcomes is consistently lower in women than men worldwide, suggesting that female biological sex is instrumental in protection. This mini-review discusses the immunomodulatory and anti-inflammatory actions of high physiological concentrations of the steroids 17beta-estradiol (E2) and progesterone (P4). We review how E2 and P4 favor a state of decreased innate immune inflammatory response while enhancing immune tolerance and antibody production. We discuss how the combination of E2 and P4 may improve the immune dysregulation that leads to the COVID-19 cytokine storm. It is intended to stimulate novel consideration of the biological forces that are protective in women compared to men, and to therapeutically harness these factors to mitigate COVID-19 morbidity and mortality. Twit Text FOAVip Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes ????Endocrinology http://www.kidney.de/pget.php?&tw=1&pmid=32730568 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32730568 #FOAvip English Wikipedia <ref>{{Cite pmid|32730568}}</ref> Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes #MMPMID32730568 Mauvais-Jarvis F; Klein SL; Levin ER Endocrinology 2020[Sep]; 161 (9): ä PMID32730568show ga Severe outcomes and death from the novel coronavirus disease 2019 (COVID-19) appear to be characterized by an exaggerated immune response with hypercytokinemia leading to inflammatory infiltration of the lungs and acute respiratory distress syndrome. Risk of severe COVID-19 outcomes is consistently lower in women than men worldwide, suggesting that female biological sex is instrumental in protection. This mini-review discusses the immunomodulatory and anti-inflammatory actions of high physiological concentrations of the steroids 17beta-estradiol (E2) and progesterone (P4). We review how E2 and P4 favor a state of decreased innate immune inflammatory response while enhancing immune tolerance and antibody production. We discuss how the combination of E2 and P4 may improve the immune dysregulation that leads to the COVID-19 cytokine storm. It is intended to stimulate novel consideration of the biological forces that are protective in women compared to men, and to therapeutically harness these factors to mitigate COVID-19 morbidity and mortality. |Antibody Formation/immunology[MESH] |Betacoronavirus[MESH] |COVID-19[MESH] |COVID-19 Drug Treatment[MESH] |Contraceptives, Oral, Hormonal/therapeutic use[MESH] |Coronavirus Infections/drug therapy/*immunology/mortality/physiopathology[MESH] |Cytokine Release Syndrome/immunology[MESH] |Drug Repositioning[MESH] |Estradiol/*immunology/therapeutic use[MESH] |Estrogen Replacement Therapy[MESH] |Estrogens/therapeutic use[MESH] |Female[MESH] |Humans[MESH] |Immune Tolerance/immunology[MESH] |Immunity, Innate/immunology[MESH] |Immunomodulation/*immunology[MESH] |Male[MESH] |Pandemics[MESH] |Pneumonia, Viral/drug therapy/*immunology/mortality/physiopathology[MESH] |Pregnancy[MESH] |Pregnancy Complications, Infectious/immunology[MESH] |Progesterone/*immunology/therapeutic use[MESH] |Progestins/therapeutic use[MESH] |SARS-CoV-2[MESH] |Selective Estrogen Receptor Modulators/therapeutic use[MESH] |Severity of Illness Index[MESH]Estradiol, Progesterone, Immunomodulation, and COVID-19 Outcomes (epmc).pdf DeepDyve Pubget Overpricing